InvestorsHub Logo
Followers 17
Posts 2115
Boards Moderated 0
Alias Born 06/18/2007

Re: None

Thursday, 11/17/2016 8:53:29 AM

Thursday, November 17, 2016 8:53:29 AM

Post# of 27409
CytoSorbents Reports Highlights from the SepsEast 2016 Critical Care Congress
PR Newswire CytoSorbents Corporation

MONMOUTH JUNCTION, N.J., Nov. 17, 2016 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its European Union approved CytoSorb® cytokine adsorber to treat deadly inflammation in critically-ill and cardiac surgery patients worldwide, reports highlights from the SepsEast 2016 Congress.


The SepsEast 2016 Congress, held from November 9-11, 2016 in Budapest, Hungary, is one of the most important critical care conferences in eastern and central Europe, drawing approximately 450 physicians and healthcare professionals from more than 25 countries. CytoSorbents was the exclusive Diamond Sponsor at the conference.

The CytoSorbents sponsored research symposium was well-attended with more than 200 participants interested in learning more about CytoSorb from the following agenda:

CytoSorb – Cytokine removal in SIRS and Sepsis
Chair: Dr. Dana Tomescu, Romania, and Dr. Janos Fazakas, Hungary
Adsorption of cytokines early in septic shock – The ACESS trial Interim Analysis
Prof. Zsolt Molnar, Hungary
When to start the therapy? Early vs late treatment in septic shock
Dr. Klaus Kogelmann, Germany
Panel discussion: Is the time ripe for a CytoSorb consensus?
Z. Molnar A. Nierhaus, K. Kogelmann, D. Tomescu, J. Fazakas
In addition, two additional lectures featured CytoSorb in the main scientific program of the conference.

Immunological interventions in sepsis – past, present, future
Dr. Axel Nierhaus, Germany
Cytokine adsorption – its place and perspectives
Dr. Dana Tomescu, Romania
Highlights from the meeting:

Prof. Zsolt Molnar presented an interim analysis of the randomized, controlled ACESS Trial, evaluating the early use of CytoSorb in patients with septic shock. The early data suggest strong improvements in hemodynamic stability in patients receiving both standard of care therapy and CytoSorb, versus those receiving standard of care alone.
Dr. Klaus Kogelmann presented data from a prospectively defined case series evaluating CytoSorb treatment in septic shock patients with multi-organ failure, correlating improved hemodynamic stability and survival when CytoSorb was used within the first 24 hours of septic shock.
Dr. Axel Nierhaus and Dr. Dana Tomescu individually described the growing usage of the CytoSorb therapy at their respective hospitals in a variety of different applications.
A panel of active CytoSorb users led by Dr. Axel Nierhaus agreed upon the first consensus statement on CytoSorb use, where they concluded:
CytoSorb is safe and easy to implement and can be used as an adjunctive therapy to standard medical treatment in patients with septic shock
CytoSorb therapy should be administered early after the onset of septic shock (within 6-24 hours) if possible
Patients with refractory septic shock may benefit from treatment with CytoSorb if they receive sufficient guideline based resuscitation and achieve good control over the infection
More frequent changes of the CytoSorb adsorber should be considered according to the clinical picture and response of the patient
All users should take part in the International CytoSorb Registry, which will facilitate better clinical studies in these complex and critically-ill patients
There are more than two dozen new publications involving CytoSorb therapy, ranging from case reports, case series, and small randomized controlled studies that have been submitted or are being prepared for submission to peer-reviewed scientific journals. These studies report on the use of CytoSorb therapy in a wide range of applications including sepsis, cardiac surgery, post-operative inflammation, liver failure, trauma, and many others.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CTSO News